Long-acting injectable antipsychotics in the treatment of schizophrenia: their role in relapse prevention

Ofer Agid University of Toronto, Department of Psychiatry, Faculty of Medicine, Toronto, Ontario, Canada; Centre for Addiction and Mental Health, Schizophrenia Program, 250 College Street, Toronto, Ontario M5T 1R8, Canada +1 416 535 8501 ext. 4862; +1 416 260 4197; [email protected]

, MD,

George Foussias University of Toronto, Department of Psychiatry, Faculty of Medicine, Toronto, Ontario, Canada; University of Toronto, Institute of Medical Science, Toronto, Ontario, Canada; Centre for Addiction and Mental Health, Schizophrenia Program, 250 College Street, Toronto, Ontario M5T 1R8, Canada +1 416 535 8501 ext. 4862; +1 416 260 4197; [email protected]

, MD MSc FRCPC &

Gary Remington University of Toronto, Department of Psychiatry, Faculty of Medicine, Toronto, Ontario, Canada; University of Toronto, Institute of Medical Science, Toronto, Ontario, Canada; Centre for Addiction and Mental Health, Schizophrenia Program, 250 College Street, Toronto, Ontario M5T 1R8, Canada +1 416 535 8501 ext. 4862; +1 416 260 4197; [email protected]

, MD PhD FRCPC

Long-acting injectable antipsychotics in the treatment of schizophrenia: their role in relapse prevention

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Long-acting injectable antipsychotics in the treatment of schizophrenia: their role in relapse prevention

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date